0000000001085306

AUTHOR

Martin Prazny

showing 1 related works from this author

Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights

2020

The current coronavirus disease 2019 (COVID-19) pandemic has led the scientific community to breach new frontiers in the understanding of human physiology and disease pathogenesis. It has been hypothesized that the human dipeptidyl peptidase 4 (DPP4) enzyme receptor may be a functional target for the spike proteins of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Since DPP4-inhibitors are currently used for the treatment of patients with type-2 diabetes (T2DM), there is currently high interest in the possibility that these agents, or incretin-based therapies (IBTs) in general, may be of benefit against the new coronavirus infection. Diabetes is associated with increased COV…

Prognostic variableCoronavirus disease 2019 (COVID-19)Pneumonia ViralIncretin030209 endocrinology & metabolism030204 cardiovascular system & hematologymedicine.disease_causeBioinformaticsIncretinsSeverity of Illness IndexGlucagon-Like Peptide-1 ReceptorBetacoronavirus03 medical and health sciences0302 clinical medicineDiabetes mellitusPandemicSeverity of illnessHumansHypoglycemic AgentsMedicinePharmacology (medical)PandemicsDipeptidyl peptidase-4CoronavirusPharmacologyDipeptidyl-Peptidase IV InhibitorsSARS-CoV-2business.industryCOVID-19medicine.diseaseDiabetes Mellitus Type 2Inflammation MediatorsCoronavirus InfectionsCardiology and Cardiovascular Medicinebusinessdiabetes DPP4 GLP1 incretins Betacoronavirus COVID-19 Coronavirus Infections Diabetes Mellitus Type 2 Dipeptidyl-Peptidase IV Inhibitors Glucagon-Like Peptide-1 Receptor Humans Hypoglycemic Agents Incretins Inflammation Mediators Pandemics Pneumonia Viral SARS-CoV-2 Severity of Illness Index
researchProduct